Ness Kevin Dean 13D and 13G filings for Brainstorm Cell Therapeutics Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-12 10:06 am Sale |
2024-02-12 | 13G | Brainstorm Cell Therapeutics Inc. BCLI |
Ness Kevin Dean | 204,000 6.250% |
-40,000 (-16.39%) |
Filing |
| 2023-04-05 10:47 am Purchase |
2023-03-17 | 13G | Brainstorm Cell Therapeutics Inc. BCLI |
Ness Kevin Dean | 244,000 9.980% |
24,000 (+10.91%) |
Filing |
| 2022-02-04 4:08 pm Purchase |
2021-11-26 | 13G | Brainstorm Cell Therapeutics Inc. BCLI |
Ness Kevin Dean | 220,000 9.100% |
220,000 (New Position) |
Filing |